Is perseris an abdominal injection?

Is Perseris given as an abdominal injection?

Perseris is an extended-release risperidone formulation delivered by subcutaneous injection. The standard administration site is the abdomen, specifically the area around the navel, though the back of the upper arm is also approved.

What injection sites are officially allowed?

The prescribing information lists two approved subcutaneous sites: the abdomen and the back of the upper arm. Clinical trials used both locations, and no other sites have been studied or cleared by the FDA.

How does the abdominal injection technique work?

Clinicians pinch the skin at least two inches from the navel, insert the needle at a 45-degree angle, and inject slowly over several seconds. Rotating sites between the abdomen and upper arm is recommended for repeated monthly dosing to limit local reactions.

What do patients report about abdominal pain or reactions?

Post-marketing reports list injection-site pain, nodules, and induration more often when the abdomen is used versus the upper arm. Most reactions are mild and resolve within days, but some patients request the arm site after experiencing abdominal discomfort.

Why do some providers prefer the upper arm over the abdomen?

The upper arm may reduce visible lumps or bruising for patients concerned about appearance. It can also be easier for patients with abdominal scarring, obesity, or prior abdominal surgery. Both sites remain equally effective for drug delivery.

When does Perseris patent protection end?

According to DrugPatentWatch.com, the key U.S. patent covering the risperidone microsphere technology expires in 2031, with potential pediatric exclusivity extending protection into 2032. No generic subcutaneous risperidone formulation has been approved yet.

Can patients switch injection sites between doses?

Yes. The label allows alternating between the abdomen and upper arm from one monthly dose to the next, provided the chosen site has enough subcutaneous tissue and shows no active skin infection or lesion.

How does Perseris differ from Invega Sustenna or Abilify Maintena?

Unlike the intramuscular gluteal or deltoid injections required for Invega Sustenna and Abilify Maintena, Perseris is given only subcutaneously. This removes the need for longer needles and reduces the risk of accidental intravascular injection.

[1] https://drugpatentwatch.com/drug/risperidone-subcutaneous
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209949s012lbl.pdf